Concurrent onabotulinumtoxina treatment of cervical dystonia and concomitant migraine
Headache: The Journal of Head and Face Pain,  Clinical Article

Winner PK et al. – Concurrent treatment with onabotulinumtoxinA is effective and well tolerated in controlling the symptoms of cervical dystonia complicated by concurrent migraine.

Methods
  • An open–label pilot study was conducted for 7.5 months in patients at least 18 years old with primary cervical dystonia of moderate severity (baseline rating of at least 20 on the Toronto Western Spasmodic Torticollis Rating Scale) complicated by migraine headache meeting the International Classification of Headache Disorders–II criteria for migraines with or without aura.
  • Each patient received 2 cycles of treatment at Visit 3 (baseline) and Visit 6 (Day 90).
  • For cervical dystonia, each patient was injected with a maximum of 175 units.
  • At the same visit, a maximum of 125 units was also injected for migraine using a fixed–site, fixed–dose injection paradigm, with additional cervical dystonia injection–site treatment to a maximum dose of 300 units.
  • Patients were assessed following onabotulinumtoxinA injection and at follow–up on Visit 4 (Day 30), Visit 5 (Day 60), Visit 6 (Day 90), and at Visits 7, 8, and 9 (Days 120, 150, and 180).
  • The primary outcome measures for this study were change in Toronto Western Spasmodic Torticollis Rating Scale total score for cervical dystonia and frequency of headache episodes per 28–day period.
  • Migraine episodes were defined as at least 4 hours of sustained pain with no upper limit.
  • An episode was considered new if the patient was pain free for at least 24 hours.
  • Secondary study end points included number of headache days per month, headache intensity, headache disability (assessed using Headache Impact Test–6 and the Migraine Disability Assessment score scales), acute headache medication use, resource utilization, and allodynia pain.
  • Adverse events were reported.

Results
  • A total of 25 patients (24 women, mean age 50.5 years; mean age of disease onset 21.9 years) were enrolled in the study.
  • Patients experienced improvement in cervical dystonia symptoms with significant reductions from baseline in Toronto Western Spasmodic Torticollis Rating Scale scores at 30, 60, 90, 120, 150, and 180 days (–9.84 ± 8.49, –12.67 ± 8.22, –13.63 ± 7.27, –14.92 ± 7.05, –4.76 ± 6.97, –14.49 ± 6.14, respectively, P < .0001 at all time points from a baseline of 31.03 ± 3.61).
  • Changes from baseline were assessed using the t–test.
  • Reductions in the number of headache episodes from baseline on concurrent onabotulinumtoxinA treatment for coexistent chronic migraine did not attain significance.
  • However, patients experienced significant reductions from baseline in the number of headache days at 90, 120, and 180 days (–3.39 ± 6.78, P = .0289; –4.29 ± 7.94, P = .0194; –4.38 ± 7.99, P = .0178, respectively, from a baseline of 15.33 ± 6.76).
  • Changes from baseline were assessed using the t–test.
  • The change from baseline in Headache Impact Test–6 total scores was significant at 30, 60, 90, 150, and 180 days (3.21 ± 4.14, P = .0009; –3.04 ± 4.04, P = .0012; –2.41 ± 2.79, P = .0006; –2.59 ± 3.87, P = .0050; –3.09 ± 3.80, respectively, from a baseline of 22.68 ± 3.20).
  • Changes from baseline were assessed using the t–test.
  • The change from baseline in Migraine Disability Assessment was significant at 120, 150, and 180 days (–38.09 ± 47.87, P < .0001, Wilcoxon signed rank test; –16.91 ± 62.69, P = .0358, Wilcoxon signed rank test; ?23.73 ± 40.57, P = .0122, t–test, respectively, from a baseline of 56.68 ± 50.41).
  • There were no serious adverse events or treatment–related disc

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Neurology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Neurology Articles

1 Clopidogrel plus aspirin aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke Journal of Clinical Neuroscience, November 13, 2014    Clinical Article

2 Marijuana use associated with lower death rates in patients with traumatic brain injuries Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center News, November 11, 2014

3 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

4 Effects of antiplatelet agents on functional outcome and cognitive status in patients with acute ischemic stroke Full Text International Journal of Gerontology, November 21, 2014    Free full text    Clinical Article

5 Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections Cerebrovascular Diseases, November 14, 2014    Clinical Article

6 Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial Cerebrovascular Diseases, October 16, 2014    Clinical Article

7 Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial The Lancet, October 17, 2014    Evidence Based Medicine    Clinical Article
Exclusive Author Commentary

8 Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation Stroke, November 25, 2014    Clinical Article

9 Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals International Journal of Cardiology, November 7, 2014    Clinical Article

10 Menopausal hormone therapy and central nervous system tumor risk: Large UK prospective study and meta-analysis International Journal of Cancer, November 7, 2014    Evidence Based Medicine

11 Effects of golden hour thrombolysis a Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) substudy JAMA Neurology, November 20, 2014    Clinical Article

12 Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial The Lancet Neurology, October 9, 2014    Clinical Article

13 The efficacy and safety of cilostazol in ischemic Stroke Patients with Peripheral Arterial Disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial International Journal of Stroke, November 18, 2014    Clinical Article

14 Neonatal vitamin D and childhood brain tumor risk International Journal of Cancer, November 17, 2014    Clinical Article

15 Emergency and critical care management of acute ischaemic stroke CNS Drugs, November 26, 2014    Clinical Article

16 Results of 2-year vitamin B treatment on cognitive performance: Secondary data from an RCT Neurology®, November 21, 2014    Clinical Article

17 Functional outcome after primary endovascular therapy or IV thrombolysis alone for stroke. an observational, comparative effectiveness study Cerebrovascular Diseases, November 24, 2014    Clinical Article

18 Dairy products and the risk of stroke and coronary heart disease: the Rotterdam Study European Journal of Nutrition, October 14, 2014    Clinical Article

19 Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women’s Health Initiative Memory Study Journal of the Academy of Nutrition and Dietetics, November 12, 2014    Clinical Article

20 The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT) The Lancet, October 30, 2014    Evidence Based Medicine    Clinical Article

Indexed Journals in Neurology: Current Opinion in Neurology, Stroke, Seizure, Cephalgia, Brain Injurymore